跳至主要内容
临床试验/NCT02886130
NCT02886130已完成不适用

Effects of Alpha-glycerylphosphorylcholine on Physical and Cognitive Performances in Varsity Volleyball Players

Université de Montréal1 个研究点 分布在 1 个国家目标入组 28 人开始时间: 2016年8月29日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
28
试验地点
1
主要终点
Change in countermovement jump performance at 4 weeks

研究概览

简要总结

In order to attain the elite level on the national scene, volleyball players need several attributes. In addition to mastering technical and tactical skills, great jumping ability is another important asset. Maximal power output needed to achieve height during a jump necessitates coordinated neuromuscular recruitment and muscle mass among others. Interestingly, there are claims that alpha-glycerylphosphorylcholine (A-GPC) increases acetylcholine synthesis and enhances exercise-induced increases in plasma growth hormone concentrations, two factors that could theoretically be associated neuromuscular transmission and muscle mass.

However, until now only a few studies have investigated the role of A-GPC in human exercise performance. Published results were mixed. One recent study showed that isometric peak force was slightly but significantly increased when subjects had ingested a daily dose of 600 mg of A-GPC over a period of 6 days (Bellar et al., JISSN, 2015).

The objective of our study is to evaluate the longer-term effects (4 weeks) using a higher dose (1000 mg/day) of A-GPC on jumping capabilities in elite male and female volleyball players.

详细描述

Our study design will be a placebo controlled, randomized, double-blind, crossover study. Varsity male and female volleyball players (n=28) will each be asked to participate in both arms of the study, i.e. placebo and A-GPC (1000 mg/kg/day). The duration of each arm of the study will be 4 weeks separated by a 7-day washout period. The order of treatment (placebo or A-GPC) will be determined randomly. Athletes will be asked to maintain their training load during the duration of the experiment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
19 Years 至 30 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Be a competitive varsity volleyball player

排除标准

  • •Regular consumption of alpha-GPC within the last 4 months
  • •Receiving drug treatment except 1) contraception (pill), and 2) treatment against asthma

研究组 & 干预措施

Placebo

Placebo Comparator

Maltodextrin tablets (4x per day) 2 x 250 mg in the morning, 2 x 250 mg 60 min before workout, 4 weeks duration

干预措施: Placebo (Dietary Supplement)

Alpha-GPC

Experimental

Alpha-GPC tablets (4x per day) 2 x 250 mg in the morning, 2 x 250 mg 60 min before workout, 4 weeks duration

干预措施: Experimental (Dietary Supplement)

结局指标

主要结局

Change in countermovement jump performance at 4 weeks

时间窗: Assessments at week 0 and at week 4 of supplementation or placebo

Jump height is calculated using two forces plates which measures the time the feet are off the platform. The athlete stands upright with weight evenly distributed over both feet. Hands are placed on the hips, and stay there throughout the test. When all is ready, the athlete squats down until the knees are bent at 90 degrees, then immediately jumps vertically as high as possible, landing back on the platform on both feet at the same time. Allow a good rest between trials. The take-off must be from both feet, with no initial steps or shuffling. They must also not pause at the base of the squat.

次要结局

  • Change in vertical jump - run up at 4 weeks(Assessments at week 0 and at week 4 of supplementation or placebo)
  • Executive function(After 4 weeks of supplementation or placebo)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Raynald Bergeron

Associate professor

Université de Montréal

研究点 (1)

Loading locations...

相似试验